Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Marie Skłodowska-Curie Action · Running

TOLERATE An integrated approach to restore tolerance in autoimmune disease

Coordinator
Katholieke Universiteit Leuven, Belgium
Runs
1 October 2022 to 30 September 2026
Status
Running
EU funding
€2.1m
Total cost
—
Partners
20 organisations in 9 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101072729

What the project is doing

In the project's own words, from its summary on CORDIS.

The TOLERATE training network aims at training DC’s to acquire the skills to develop different innovative strategies to treat autoimmune diseases, to identify the most promising strategies or a combination of strategies, to setup clinical trials and to develop a roadmap to bring a novel therapeutic agent to the market. This all will be done in a highly interdisciplinary and intersectoral environment. Interdisciplinarity allows to introduce innovative tolerogenic therapies developed for cancer, Chimer Antigen Receptor (CAR)-T cell therapies, into the world of autoimmune disease and to apply nanotechnology and protein-engineered tolerogenic vaccines to re-establish immune tolerance in autoimmune disease.

Both the presence of academia and industry provides a platform for in-depth preclinical studies and a realistic possibility for future commercialization of the novel therapies. Clinicians in the consortium with expertise in setting-up and running clinical trials for novel drugs assure that developed novel therapies in TOLERATE will find their way to the clinic in the future. Developing novel therapies for autoimmune diseases goes close together with a thorough knowledge on the long-term consequences of living with an autoimmune disease.

Since many autoimmune diseases are rare diseases, setting up international uniform databases and biobanks is crucial to understand the long-term pathophysiology of the disease and to guarantee optimal use of (novel) therapies. TOLERATE will train 8 DCs who will hence has the expertise and skills to work in and setup interdisciplinary and intersectoral projects. The ground-breaking training programme will provide the DC’s with a unique clinical training.

Additional training in ethical, regulatory and legal aspects together with a training in innovation management of therapeutics and diagnostics for autoimmune diseases will prepare the DCs for the European job market.

Topics

Who is involved

OrganisationCityCountryRole
Katholieke Universiteit LeuvenLeuvenBelgiumCoordinator
AnicellsNielBelgiumAssociatedpartner
AnicellsNielBelgiumParticipant
Universiteit AntwerpenAntwerpenBelgiumAssociatedpartner
Universiteit AntwerpenAntwerpenBelgiumParticipant
Helmholtz-Zentrum Dresden-Rossendorf eVDresdenGermanyParticipant
Technische Universitaet DresdenDresdenGermanyAssociatedpartner
Immudex ApsVirumDenmarkAssociatedpartner
Ahead Therapeutics SLCerdanyola Del VallesSpainParticipant
Biokit Research & Development S.L.U.Llica d'AmuntSpainAssociatedpartner
Universitat Autonoma De BarcelonaCerdanyola Del VallesSpainAssociatedpartner
Assistance Publique Hopitaux De ParisParisFranceParticipant
Sorbonne UniversiteParisFranceAssociatedpartner
Semmelweis EgyetemBudapestHungaryParticipant
Royal College of Surgeons in IrelandDublin 2IrelandParticipant
Innovation Acta SRLSienaItalyAssociatedpartner
European Hematology AssociationDen HaagNetherlandsAssociatedpartner
Stichting Amsterdam UmcAmsterdamNetherlandsAssociatedpartner
Stichting Sanquin BloedvoorzieningAmsterdamNetherlandsParticipant
Universiteit Van AmsterdamAmsterdamNetherlandsAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI